Table 5.

Mediation of the relationship between log PAT or log PAT/SAT ratio on GIR by RQ, fasting FFA, and log HMW adiponectin

	Log PAT				Log PAT/SAT
	Males (N=36)		Females (N=47)		(N=83)
Model	β (±SE)*, p-value	Mediation effect size†	β (±SE)*, p-value	Mediation effect size†	β (±SE)*, p-value	Mediation effect size†
Model 1‡	−0.18 (±2.38), 0.940		3.36 (±1.96), 0.097		−2.08 (±1.03), 0.047
Model 2§	1.30 (±2.06), 0.536	−1.59 (−8.23, 4.29)	0.55 (±1.65), 0.740	4.00 (0.13, 9.33)	−1.33 (±0.86), 0.130	−0.75 (−3.03, 1.39)
Model 3||	−0.69 (±2.53), 0.788	1.03 (−2.22, 5.69)	3.34 (±2.00), 0.105	0.04 (−1.56, 1.75)	−2.12 (±1.05), 0.047	0.08 (−0.54, 0.83)
Model 4#	−0.40 (±2.00), 0.844	0.43 (−5.26, 6.33)	3.38 (±1.78), 0.067	−0.03 (−3.92, 3.85)	−2.36 (±0.94), 0.014	0.51 (−1.14, 2.32)
Model 5¶	−0.31 (±2.39), 0.897	0.26 (−2.65, 3.72)	3.32 (±2.02), 0.110	0.08 (−1.80, 2.14)	−2.17 (±1.04), 0.042	0.15 (−0.52, 1.08)

Abbreviations: PAT, pericardial adipose tissue; SAT, subcutaneous adipose tissue; GIR, glucose infusion rate; RQ, respiratory quotient; FFA, free fatty acids; HMW, high molecular weight; BMI, body mass index; VAT, visceral adipose tissue; LDL, low-density lipoprotein

^*per 1 SD

^†Mediation effect size estimated using product of coefficients method with unstandardized coefficients; 95% CI’s estimated using the distribution of the product method

^‡Adjusted for diabetes, race, age, systolic blood pressure, LDL, log triglycerides, on blood pressure and hypertension lowering medication, percent of energy from fats and carbohydrates, square-root transformed minutes of moderate intensity-equivalent activity weekly, BMI, log VAT, and log PAT/SAT ratio or log PAT, respectively; additionally adjusted for sex in log PAT/SAT ratio models

^§Adjusted for variables in Model 1 + RQ

^||Adjusted for variables in Model 1 + fasting FFA

^#Adjusted for variables in Model 1 + FFA suppression

^¶Adjusted for variables in Model 1 + log HMW adiponectin